Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995729 | 0.85 | ALDH1A1 (0.70) | ALDH1A1IMPDH2KDM4EUBE2NPOLB | |
| SCHEMBL2275437 | 0.85 | ALDH1A1 (0.70) | ALDH1A1IMPDH2KDM4EUBE2NPOLB | |
| SCHEMBL14612755 | 0.84 | ALDH1A1 (0.47) | ALDH1A1IMPDH2KDM4EMAPTLMNA | |
| SCHEMBL1093940 | 0.82 | ALDH1A1 (0.62) | ALDH1A1IMPDH2KDM4EPOLBGSK3B | |
| SCHEMBL16502064 | 0.82 | ALDH1A1 (0.62) | ALDH1A1IMPDH2KDM4EPIM3GSK3B | |
| SCHEMBL1093250 | 0.82 | ALDH1A1 (0.76) | ALDH1A1IMPDH2KDM4EPOLBLMNA | |
| SCHEMBL30995726 | 0.82 | ALDH1A1 (0.62) | ALDH1A1IMPDH2KDM4EPOLBGSK3B | |
| SCHEMBL27957969 | 0.80 | ALDH1A1 (0.44) | ALDH1A1IMPDH2KDM4EUBE2NPOLB | |
| SCHEMBL13537257 | 0.80 | ALDH1A1 (0.59) | ALDH1A1IMPDH2KDM4EUBE2NPOLB | |
| SCHEMBL7832439 | 0.80 | ALDH1A1 (0.59) | ALDH1A1IMPDH2KDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912576-B | Cyclic or spirocyclic diamine pyrimidine-hydroxamic acids and their use | 华东理工大学 | 2021-11-19 | — | — | CN | disclosed |
| CN-109912576-A | Cyclic annular or loop coil Diamines pyrimidine-hydroxamic acid and application thereof | 华东理工大学 | 2019-06-21 | — | — | CN | disclosed |
| CN-108689906-A | The hydrazide derivatives and application thereof of indoles substitution | 广东东阳光药业有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-8173646-B2 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-20110190283-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7790716-B2 | fatty acid biosynthesis inhibitors such as E)-3-(6-aminopyridin-3-yl)-N-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)acrylamide, used fro the treatment of bacterial infections; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20090275572-A1 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7557125-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-07-07 | — | — | US | disclosed |
| US-7524843-B2 | N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide as an enzyme inhibitor for both Fab I and Fab K which are used in the biosynthesis of fatty acids; enoyl-acyl-carrier protein renamed Fab 1; bactericides; fungicides; Staphylococcus aureus; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-04-28 | — | — | US | disclosed |
| US-20080125423-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2008-05-29 | — | — | US | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| CN-1197860-C | FAB I inhibitors | SMITHKLINE BEECHAM CORP (CA) | 2005-04-20 | — | — | CN | disclosed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
| CN-1378542-A | Antigen binding fragment I inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | CN | disclosed |
| CN-1077572-C | Substituted bisindolylmaleimides for inhibition of cell proliferation | HOFFMANN LA ROCHE (CH) | 2002-01-09 | — | — | CN | disclosed |
| CN-1226249-A | Substituted bisindolylmaleimides for inhibition of cell proliferation | HOFFMANN LA ROCHE (CH) | 1999-08-18 | — | — | CN | disclosed |
| US-5891901-A | ANTICARCINOGENIC AGENTS OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | ALDH1A1 2491/4885IMPDH2 1790/4885KDM4E 4583/4885 |
| US-20090275572-A1 | FAB I INHIBITORS | SERPINB1, TFPI, TFPI2 | ALDH1A1 2491/4885IMPDH2 1790/4885KDM4E 4583/4885 |
| US-20080125423-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | ALDH1A1 2491/4885IMPDH2 1790/4885KDM4E 4583/4885 |
| US-20110190283-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | ALDH1A1 2491/4885IMPDH2 1790/4885KDM4E 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.